Clinical Convergence®: New Management Approaches in Bladder Cancer from Collaborative Care to Immunotherapy

Title:

Clinical Convergence®: New Management Approaches in Bladder Cancer from Collaborative Care to Immunotherapy

Topic: Hematology-Oncology
Relevant Terms: Bladder Cancer
Primary Audience: Oncologists and oncology nurse practitioners and physician assistants
Launch Date: 21-Mar-17
Credits: AMA PRA Category 1 Credit
Expiration Date: 21-Mar-18
Curriculum Name: Clinical Convergence®: New Management Approaches in Bladder Cancer from Collaborative Care to...

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Appropriately utilize currently approved treatments for advanced or metastatic urothelial bladder cancer to optimize patient outcomes
  2. Incorporate neoadjuvant chemotherapy into the multidisciplinary management of patients with advanced or metastatic urothelial bladder cancer
  3. Describe how emerging immunotherapies can be incorporated for management of patients with advanced or metastatic urothelial bladder cancer
  4. Employ a strong patient-provider collaborative approach to managing patients with advanced or metastatic urothelial bladder cancer that includes patient education, engagement, and shared decision making

    Faculty

    Elizabeth R. Plimack, MD, MS
    Chief, Division of Genitourinary Medical Oncology
    Director, Genitourinary Clinical Research
    Associate Professor, Department of Hematology/Oncology
    Fox Chase Cancer Center, Temple University Health System
    Philadelphia, PA
    Alexander Kutikov, MD
    Associate Professor
    Department of Surgical Oncology
    Fox Chase Cancer Center, Temple University Health System
    Philadelphia, PA
    PHYSICIAN CONTINUING MEDICAL EDUCATION
    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and RMEI Medical Education, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
     
    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
     
    DISCLOSURE OF CONFLICTS OF INTEREST
    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
     
    The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
    • Elizabeth R. Plimack, MD, MS, has affiliations with Acceleron, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, and Pfizer (Consulting Fees and Contracted Research); Genentech, Novartis, Roche, and Synergene (Consulting Fees); and Aveo, Dendreon, GlaxoSmithKline, Merck, and Peloton (Contracted Research).
    • Alexander Kutikov, MD, has affiliations with Genomic Health, Inc. (Consulting Fees) and Visible Health, Inc. (Ownership Interest).
    RMEI Medical Education, LLC
    • Jacqui Brooks, MBBCh, MRCPsych, has no affiliations with commercial interests to disclose.
    • Marie N. Becker, PhD, has no affiliations with commercial interests to disclose.
    • Amy Reeve has no affiliations with commercial interests to disclose.
    Postgraduate Institute for Medicine
    The PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN, and Jan Schultz, MSN, RN, CHCP, have nothing to disclose.
     
    DISCLAIMER
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities
     
    DISCLOSURE OF UNLABELED USE
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
     
    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
     
    Estimated time to complete: 1.0 hour
    Media: Internet
     
    FEE INFORMATION
    There is no fee for this educational activity.
     
    COMMERCIAL SUPPORT
    This activity is jointly provided by Postgraduate Institute for Medicine and RMEI Medical Education, LLC. This activity is supported by an independent educational grant from Genentech.
     
    HOW TO RECEIVE CREDIT
    By reviewing the course content and successfully completing the post-test and evaluation, physicians, nurse practitioners, and physician assistants are entitled to receive up to 1.0 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print from your user history page. Users must:
     
    • Read the learning objectives and faculty disclosures.
    • Participate in the activity.
    • Complete the activity evaluation.
    Physicians, nurse practitioners, and physician assistants who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
     
    COURSE VIEWING REQUIREMENTS
    Supported Browsers:
    Internet Explorer 9.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1
    Google Chrome 28.0+ for Windows, Mac OS, or Linux
    Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
    Safari 6.0+ for Mac OSX 10.7 and above
     
    Supported Phones & Tablets:
    Android 4.0.3 and above
    iPhone/iPad with iOS 6.1 or above.